Global Radiopharmaceuticals in Nuclear Medicine Market Growth 2025-2031

Global Radiopharmaceuticals in Nuclear Medicine Market Growth 2025-2031

The global Radiopharmaceuticals in Nuclear Medicine market size is predicted to grow from US$ 6533 million in 2025 to US$ 10110 million in 2031; it is expected to grow at a CAGR of 7.6% from 2025 to 2031.

Radiopharmaceuticals are radioisotopes bound to biological molecules able to target specific organs, tissues or cells within the human body. These radioactive drugs can be used for the diagnosis and, increasingly, for the therapy of diseases.

Radiopharmaceuticals are radioactive compounds administered to the patient, and monitored via specific imaging devices, for diagnosis and therapeutic purposes. It is composed of a radioisotope bond to an organic molecule. The organic molecule conveys the radioisotope to specific organs, tissues or cells. The radioisotope is selected for its properties. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases (for example, brachytherapy). Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.

The radiopharmaceutical market is driven primarily by the growing prevalence of cancer and cardiovascular diseases, which require precise diagnostic tools for early detection and treatment. The increasing adoption of nuclear medicine imaging techniques, such as PET and SPECT scans, has further fueled demand for radiopharmaceuticals. Additionally, technological advancements in radiopharmaceuticals, along with the development of new radioisotopes for more targeted therapies, are expanding the applications of these drugs, making them critical in personalized medicine.

Despite the promising growth, the radiopharmaceutical market faces significant challenges, including the high cost of production and the short half-life of many radioisotopes, which complicates distribution and storage. Regulatory hurdles are another barrier, as radiopharmaceuticals require stringent approval processes due to their radioactive nature. Moreover, limited availability of specialized infrastructure and the shortage of trained professionals in nuclear medicine also hinder widespread adoption, especially in developing regions.

There is widespread awareness of the use of radiation and radioisotopes in medicine, particularly for diagnosis (identification) and therapy (treatment) of various medical conditions. In developed countries (a quarter of the world population) about one person in 50 uses diagnostic nuclear medicine each year, and the frequency of therapy with radioisotopes is about one-tenth of this.

Nuclear medicine uses radiation to provide information about the functioning of a person's specific organs, or to treat disease. In most cases, the information is used by physicians to make a quick diagnosis of the patient's illness. The thyroid, bones, heart, liver, and many other organs can be easily imaged, and disorders in their function revealed. In some cases radiation can be used to treat diseased organs, or tumours.

Over 10,000 hospitals worldwide use radioisotopes in medicine, and about 90% of the procedures are for diagnosis. The most common radioisotope used in diagnosis is technetium-99 (Tc-99m) accounting for about 80% of all nuclear medicine procedures and 85% of diagnostic scans in nuclear medicine worldwide.Over 50 million nuclear medicine procedures are performed each year, and demand for radioisotopes is increasing.

LP Information, Inc. (LPI) ' newest research report, the “Radiopharmaceuticals in Nuclear Medicine Industry Forecast” looks at past sales and reviews total world Radiopharmaceuticals in Nuclear Medicine sales in 2024, providing a comprehensive analysis by region and market sector of projected Radiopharmaceuticals in Nuclear Medicine sales for 2025 through 2031. With Radiopharmaceuticals in Nuclear Medicine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Radiopharmaceuticals in Nuclear Medicine industry.

This Insight Report provides a comprehensive analysis of the global Radiopharmaceuticals in Nuclear Medicine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Radiopharmaceuticals in Nuclear Medicine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Radiopharmaceuticals in Nuclear Medicine market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Radiopharmaceuticals in Nuclear Medicine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Radiopharmaceuticals in Nuclear Medicine.

This report presents a comprehensive overview, market shares, and growth opportunities of Radiopharmaceuticals in Nuclear Medicine market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Diagnostic Radiopharmaceuticals
Therapy Radiopharmaceuticals

Segmentation by Application:
Oncology
Cardiology
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Cardinal Health
GE Healthcare
Jubilant Pharma
Novartis
Curium Pharma
SIEMENS
Lantheus
Bracco Imaging
Bayer
Eli Lilly
Aurobindo Pharma
Mundipharma
China Isotope & Radiation
Dongcheng

Key Questions Addressed in this Report

What is the 10-year outlook for the global Radiopharmaceuticals in Nuclear Medicine market?

What factors are driving Radiopharmaceuticals in Nuclear Medicine market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Radiopharmaceuticals in Nuclear Medicine market opportunities vary by end market size?

How does Radiopharmaceuticals in Nuclear Medicine break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.